Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gore

Showing results (281-290 of 306) with videos related to

Pageof 31
Sort By:
Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Myelodysplastic syndromesPeter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
The Journal of Clinical Investigation|December 7, 2023
PD-1H/VISTA mediates immune evasion in acute myeloid leukemiaTae Kon Kim, Xue Han, Qianni Hu, et al.
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
The Journal of Biological Chemistry|May 3, 2011
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7qLi Zhou, Joanna Opalinska, Davendra Sohal, et al.
Blood Advances|February 11, 2026
A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History StudyAmy E DeZern, Nancy Gillis, Michael Otterstatter, et al.
Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Leukemia & Lymphoma|May 22, 2019
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromesMikkael A Sekeres, Steven D Gore, Donald M Stablein, et al.
Pageof 31

Showing results (281-290 of 306) with videos related to

Sort By:
Pageof 31
Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Myelodysplastic syndromesPeter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
The Journal of Clinical Investigation|December 7, 2023
PD-1H/VISTA mediates immune evasion in acute myeloid leukemiaTae Kon Kim, Xue Han, Qianni Hu, et al.
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
The Journal of Biological Chemistry|May 3, 2011
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7qLi Zhou, Joanna Opalinska, Davendra Sohal, et al.
Blood Advances|February 11, 2026
A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History StudyAmy E DeZern, Nancy Gillis, Michael Otterstatter, et al.
Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Leukemia & Lymphoma|May 22, 2019
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromesMikkael A Sekeres, Steven D Gore, Donald M Stablein, et al.
Pageof 31